Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma

  • Mang Ngaih Ciin Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
  • Tanakorn Proungvitaya Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
  • Temduang Limpaiboon 1) Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand 2) Cholangiocarcinoma Research Institute (CARI), Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
  • Ubon Cha’on Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
  • Sittiruk Roytrakul National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani 12120, Thailand
  • Siriporn Proungvitaya Mail 1) Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand 2) Cholangiocarcinoma Research Institute (CARI), Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Keywords:
Cystatin C; CKD-EPI equation, Glomerular filtration rate; Cholangiocarcinoma

Abstract

Background: Cholangiocarcinoma (CCA) is the second most common primary hepatobiliary cancer. These patients have meager prognosis and short-term survival. Precise assessment of glomerular filtration rate is a fundamental aspect of clinical care in cancer patients. Cystatin C has been proposed to be superior to creatinine, a well-known marker of renal function. This study aimed to evaluate cystatin C as a marker of GFR calculation in CCA patients.

Materials and Methods: One hundred thirty serum samples from CCA patients and 32 from controls were included in this study. Serum cystatin C was measured using immunoturbidity assay. Estimated glomerular filtration rate was calculated by three equations established by chronic kidney disease epidemiology collaboration (based on creatinine and/or cystatin C).

Results: Serum cystatin C in CCA patients was higher than that of controls (p=0.0002). Cystatin C was positively correlated with BUN in CCA group (p=0.019). eGFR based on cystatin C and based on both cystatin C and creatinine in CCA was low with significantly different from those of control (p<0.001). Although there was no difference in eGFR using three equations in control, creatinine based eGFR was high with significantly different from eGFR based on cystatin C and on both creatinine and cystatin C in CCA (P=0.000).  Proportion in each eGFR stage by three equations showed a high sensitivity with significantly different in CCA (p<0.05).

Conclusion: There was a high sensitivity of cys C with significant difference between creatinine and/or cystatin C based eGFR in CCA patients. It should take account into consideration of mild changes in eGFR by cystatin C which is important in managing drug dosage for CCA patients.

References

1. Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29(2):245–52.
2. Sripa B, Kaewkes S, Sithithaworn P, et al. Liver Fluke Induces Cholangiocarcinoma. PLoS Med. 2007; 4(7):e201.
3. Woradet S, Songserm N, Promthet S, et al. Health-related quality of life and survival of cholangiocarcinoma patients in northeastern region of Thailand. PLoS One. 2016; 11(9): e0163448.
4. Cosmai L, Porta C, Gallieni M. Chapter 13 : CKD as a Complication of Cancer 1–6, 2016.
5. Stevens LA. Measurement of Glomerular Filtration Rate. In: Nephrology Secrets 26–30, 2012.
6. Robinson R, Tait CD, Somov P, et al. Estimated glomerular filtration rate is unreliable in detecting renal function loss during follow-up after cystectomy and urinary diversion. Int Urol Nephrol. 2016; 48(4):511–5.
7. Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007; 18(8):1314–21.
8. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008; 3(2):348–54.
9. Raj GV, Iasonos A, Herr H, et al. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006; 24(19):3095–100.
10. Funakoshi Y, Fujiwara Y, Kiyota N, et al. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn J Clin Oncol. 2013; 43(3):271–7.
11. Mussap M, Vestra MD, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002; 61(4):1453–61.
12. Qutb A, Syed G, Tamim HM, et al. Cystatin C-based formula is superior to MDRD, Cockcroft-Gault and Nankivell formulae in estimating the glomerular filtration rate in renal allografts. Exp Clin Transplant. 2009; 7(4):197–202.
13. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65(4):1416–21.
14. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002; 40(2):221–6.
15. Demirtaş S, Uzunoǧlu N, Can M, et al. Serum cystatin C levels in gastric cancer patients: Scientific letter. Turkiye Klin J Med Sci. 2007; 27(3):442–4.
16. Böike E, Schieren G, Gripp S, et al. Cystatin C - A fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Strahlenther Onkol. 2011; 187(3):191–201.
17. Nakai K, Kikuchi M, Fujimoto K, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008; 12(2):132–9.
18. Kos J, Werle B, Lah T, et al. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. INT J BIOL MARKER. 2000;15(1):84–9.
19. Dr. Levey A.S. MDRD GFR Equation - MDCalc. Available from: https://www.mdcalc.com/mdrd-gfr-equation
20. Estimated Glomerular Filtration Rate (eGFR) | National Kidney Foundation. Available from: https://www.kidney.org/atoz/content/gfr.
21. Sjöström P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest. 2005; 65(2):89-91.
22. Massey D. Commentary: clinical diagnostic use of cystatin C. J Clin Lab Anal. 2004; 18(1):55-60.
23. Chaudhary SS, Shah JP, Mahato RV. Interference of Bilirubin in Creatinine Value Measurement by Jaffe Kinetic Method. ACCLM. 2015; 1(1): 25-28.
24. Nigam PK. Bilirubin Interference in Serum Creatinine Estimation by Jaffe's kinetic Method and Its Rectification in Three Different Kits. Indian J Clin Biochem. 2016; 31(2):237-9.
25. Trimarchi H, Muryan A, Martino D, et al. Creatinine- vs. cystatin C-based equations compared with 99mTcDTPA scintigraphy to assess glomerular filtration rate in chronic kidney disease. J Nephrol. 2012; 25(6): 1003-15.
26. Giglio D. A new equation for estimating glomerular filtration rate in cancer patients. Chemotherapy. 2014; 60(1):63–72.
27. Benöhr P, Grenz A, Hartmann JT, et al. Cystatin C - A marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res. 2006; 29(1):32–5.
28. Feldman HI, Inker LA, Coresh J, et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med. 2012; 367(1):20–9.
29. Mussap M, Vestra MD, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002; 61(4):1453–61.
30. LeBricon T, Leblanc I, Benlakehal M, et al. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med. 2005; 43(9):953–7.
31. Ben¨ohr P, Grenz A, Hartmann J.T, M¨uller G.A, Blaschke S. CystatinC-amarker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res. 2006; 29(1):32–35.
32. ˇStabuc B, Vrhovec L, ˇStabuc-ˇSilih M, et al. Improved prediction of decreased creatinine clearance byserum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem. 2000; 46(2):193–7.
33. Al-Tonbary YA, Hammad AM, Zaghloul HM, et al. Pretreatment cystatin C in children with malignancy: can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase? J Pediatr Hematol Oncol 2004; 26(6):336–41.
34. Bodnar L, Wcislo GB, Smoter M, et al. Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res. 2010; 33(5):360–7.
35. Kume M, Yasui H, Yoshikawa Y, et al. Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol. 2012; 69(6):1537–44.
36. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron. 1977; 18(3):182–4.
37. Launay-Vacher V, Izzedine H, Rey J-B, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004; 10(5):CR209-12.
38. Kutluk Cenik B, Sun H, Gerber DE. Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer. 2013; 80(3):326–332.
39. Tsao CK, Moshier E, Seng SM, et al. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012; 10(1):15–20.
40. Barraclough LH, Field C, Wieringa G, et al. Estimation of renal function - What is appropriate in cancer patients? Clin Oncol (R Coll Radiol). 2008; 20(10):721–6.
41. Amirrasooli H, Tabatabaeefar M, Moeani B. The efficacy of serum cystatin c and creatinine to diagnose impaired renal function in cancer patients under treatment with cisplatin. UHOD - Uluslararasi Hematol Derg. 2015; 25(1):51–9.
Published
2020-07-02
How to Cite
1.
Ciin MN, Proungvitaya T, Limpaiboon T, Cha’on U, Roytrakul S, Proungvitaya S. Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma. Int J Hematol Oncol Stem Cell Res. 14(3):157-166.
Section
Original Article(s)